VX 15

Drug Profile

VX 15

Alternative Names: Anti-SEMA4D antibody - Vaccinex; moAb VX15/2503; VX15; VX15/2503

Latest Information Update: 27 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vaccinex
  • Developer Children's Oncology Group; Emory University; Merck KGaA; National Cancer Institute (USA); Teva Pharmaceutical Industries; Vaccinex
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD100 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Huntington's disease
  • Phase I/II Non-small cell lung cancer; Osteosarcoma; Solid tumours
  • Phase I Colorectal cancer; Pancreatic cancer
  • No development reported Multiple sclerosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 07 Feb 2018 Jonsson Comprehensive Cancer Center in collaboration with National Cancer Institute plans a phase I trial for Melanoma (Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (NCT03425461)
  • 16 Jan 2018 Phase-I/II clinical trials in Osteosarcoma (In adolescents, In adults, In children, In infants, Recurrent, Second-line therapy or greater) in USA (IV) (NCT03320330; 3318336)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top